Please login to the form below

Not currently logged in

Aimmune Therapeutics

This page shows the latest Aimmune Therapeutics news and features for those working in and with pharma, biotech and healthcare.

DBV refiles peanut allergy immunotherapy in the US

DBV refiles peanut allergy immunotherapy in the US

four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... GlobalData has predicted that Aimmune’s drug will have two-thirds of the market in 2027, with DBV’s drug

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy. ... However, Aimmune reported in February 2019 that the FDA had initially determined that the drug, as an allergenic extract, was exempt from the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Now a US biotech company, Aimmune, looks set to bring the first treatment to market by the end of this year. ... Aimmune Therapeutics submitted the drug to the FDA on 21 December.

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food. ... acquisition - company. 80. Arsia Therapeutics/ Eagle Pharmaceuticals. viscosity

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...